The recently described human anion channel Anoctamin (ANO) protein family comprises at least ten members, many of which have been shown to correspond to calcium-activated chloride channels. To date, the only reported human mutations in this family of genes are dominant mutations in ANO5 (TMEM16E, GDD1) in the rare skeletal disorder gnathodiaphyseal dysplasia. We have identified recessive mutations in ANO5 that result in a proximal limb-girdle muscular dystrophy (LGMD2L) in three French Canadian families and in a distal non-dysferlin Miyoshi myopathy (MMD3) in Dutch and Finnish families. These mutations consist of a splice site, one base pair duplication shared by French Canadian and Dutch cases, and two missense mutations. The splice site and the duplication mutations introduce premature-termination codons and consequently trigger nonsense-mediated mRNA decay, suggesting an underlining lossof-function mechanism. The LGMD2L phenotype is characterized by proximal weakness, with prominent asymmetrical quadriceps femoris and biceps brachii atrophy. The MMD3 phenotype is associated with distal weakness, of calf muscles in particular. With the use of electron microscopy, multifocal sarcolemmal lesions were observed in both phenotypes. The phenotypic heterogeneity associated with ANO5 mutations is reminiscent of that observed with Dysferlin (DYSF) mutations that can cause both LGMD2B and Miyoshi myopathy (MMD1). In one MMD3-affected individual, defective membrane repair was documented on fibroblasts by membrane-resealing ability assays, as observed in dysferlinopathies. Though the function of the ANO5 protein is still unknown, its putative calcium-activated chloride channel function may lead to important insights into the role of deficient skeletal muscle membrane repair in muscular dystrophies.
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Muscular dystrophies encompass a large and diverse group of inherited diseases defined by skeletal muscle weakness and atrophy. Among these, the limb-girdle muscular dystrophies (LGMD) represent a group of both dominant and recessive disorders, characterized by predominant proximal limb muscle weakness, with 18 known causal genes. 1, 2 The majority of the proteins involved in LGMD are important for maintaining the integrity of the sarcolemmal membrane, which is susceptible to injury because of the high mechanical stress imposed on muscle fibers during muscle contraction. 
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The human Anoctamins (ANO) compose a family of at least ten proteins all exhibiting eight transmembrane domains and a DUF590 domain of unknown function. 13, 14 Recently, ANO1 (MIM 610108), ANO2 (MIM 610109), ANO6 (MIM 608663), ANO8 (MIM 610216), and ANO9 have been recognized to code for the elusive calciumactivated chloride channels (CaCC); [15] [16] [17] [18] [19] [20] however, the function of ANO5 (MIM 608662) is unknown. In this study we report that recessive mutations in Anoctamin 5 (ANO5) cause both a proximal muscular dystrophy, LGMD2L (MIM 611307), and the distal Miyoshi myopathy MMD3. A previous study mapped LGMD2L, a novel recessive form of LGMD associated with prominent asymmetrical quadriceps femoris and biceps brachii atrophy, to chromosome 11p12-p13 in a cohort of French Canadian (FC) families. 21 l'Université de Montréal ethics committee was obtained for all participants. In Family IX we identified a homozygous nucleotide substitution (c.1295C>G) in genomic DNA, which creates a putative splice donor site within exon 13 as calculated by NetGene2 and Human Splicing Finder v2.4 ( Figures 1A and 1B ). Amplification and sequencing of patient muscle cDNA confirmed the aberrant splicing of exon 13 that results in the deletion of the last 38 nucleotides of this exon ( Figures 1C and 1D ), leading to a frameshift and a predicted premature truncation (p.Ala432GlyfsX49). Segregation of this variant in Family IX was confirmed by sequencing the genomic DNA of exon 13 in all siblings ( Figure 1A ). The same mutation was identified in homozygote state in the two cases belonging to the FC Family XXXI ( Figure 1A ). The two families are not known to be related and come from different regions, but share a six STR markers haplotype (covering 3.6 Mb), suggesting that it is the same historical mutation that segregates in these families (data not shown). The third LGMD2L FC Family XXIX was heterozygous for two other variants: c.191 dupA in exon 5 (p.Asn64LysfsX15) and c.692G>T in exon 8 (p.G231V) ( Figure 1E ). The G231 residue is evolutionary conserved ( Figure 1F ) and is predicted to be located in the putative intracellular N-terminal tail ( Figure 2D ). Sequencing of the entire 87 kb genomic region of ANO5 is underway to identify mutations in other FC LGMD families. Further evidence that ANO5 mutations cause muscular dystrophy came from an independent study of families presenting with a distal non-dysferlin Miyoshi myopathy. Informed consents approved by the Kainuu Central Hospital (Finland), the Academic Medical Centre (The Netherlands), and the University of Durham (United Kingdom) ethical committees were obtained for these families. Two Miyoshi myopathy families, in which mutations in DYSF and linkage to the 10p MMD2 locus had been excluded, 23 were genotyped via the Affymetrix Gen- ANO5 is predicted to produce several alternatively spliced isoforms, with the major isoform in muscle retaining all 22 exons. 25 Based on the predicted full coding sequence (NCBI reference sequence NM_213599.2), it is expected that the mutations c.1295C>G (LGMD2L) and c.191 dupA (LGMD2L and MMD3) lead to a frameshift and premature truncation (p.Ala432GlyfsX49 and p.Asn64LysfsX15, respectively; Figure 2D ). As is often the case with mRNAs containing premature termination codons, a translation-coupled nonsense-mediated RNA decay (NMD) mechanism may lead to their more rapid degradation. 26 To test whether transcripts carrying the mutations c.1295C>G and c.191 dupA are subject to NMD, lymphoblastoid cell lines isolated from EBV-transformed lymphocytes were grown in IMDM medium (Invitrogen, Carlsbad, CA) supplemented with 10% Fetal Bovine serum (Invitrogen) and incubated for 9 hr with 0.1% DMSO (vehicle) or 100 mg/mL of cycloheximide (Sigma, St. Louis, MO), a translation inhibitor. Quantitative RT-PCR were performed in triplicate on extracted RNA, and expression of ANO5 was normalized to a set of three control genes (GAPDH [MIM 138400], PUM1 [MIM 607204], and RPL13A) via QBase, a modified DDCt method, 27 at the Génome Québec and Université de Sherbrooke RNomics Centre. All controls and cases demonstrated an increase in the relative ANO5 expression as a consequence of cycloheximide treatment ( Figure 3A) ; however, the differential ANO5 expression between cycloheximide-treated and untreated cells was significantly greater in patients homozygous for c.1295C>G (n ¼ 2) versus controls (n ¼ 3, p < 0.001, Student's t test; Figure 3B ), suggesting that the mutated transcripts were protected from NMD when translation was inhibited. The approximate 5-fold increase observed for case XXIX-II-1 ( Figure 3A) , as compared to the 8-and 9-fold increases observed for the two c.1295C>G aberrant splicing mutation homozygote cases, is in agreement with her (D) Predicted structure of human ANO5 and the relative position of the GDD1, LGMD2L, and MMD3 mutations. ANO5 is predicted to contain eight transmembrane (TM) domains with both the N-terminal and the C-terminal regions located intracellularly. The DUF590 domain contains at last three TM domains (TM6-8). The MMD3 R758C mutation that is associated with defective membrane repair is located extracellularly as are the two GDD mutations. The LGMD2L mutations and one MMD3 mutation are located to intracellular regions.
heterozygote state for a premature termination (c.191 dupA) and missense (c.692G>T, G231V) mutations. These results strongly suggest that the two variants c.1295C>G and c.191 dupA are associated with a loss of ANO5 function. Previously, dominant ANO5 mutations have been reported in two families with gnathodiaphyseal dysplasia (GDD [MIM 166260]), a rare skeletal syndrome characterized by bone fragility, cement-osseous lesions of the maxilla and mandible, and diaphyseal sclerosis of tubular bones. 28 In these patients no other abnormalities in nonskeletal tissues have been reported. 28 The missense mutations in GDD patients affect a conserved cysteine located in an extracellular loop of ANO5, similar to the R758C mutation found in MMD3 patients ( Figure 2D ). However, because GDD is a dominant disease, it was hypothesized that the mutations in these patients cause a gain-of-function effect predominantly in skeletal tissues. 28 The only two available polyclonal antibodies generated against N-and C-terminal epitopes of mouse Ano5 29 failed to recognize the normal human protein on western blots generated from transfected HeLa and Cos-1 cell lysates. By immunofluorescence, nonspecific perimembranous and cytoplasmic staining was detected in skeletal muscle (data not shown), thereby precluding the testing of the impact of the mutations on the expression and localization of ANO5 in patient muscle. Table 1 summarizes the clinical findings for patients carrying ANO5 mutations that are also presented in greater details in Table S1 available online. LGMD2L patients are characterized by late-onset proximal scapular and pelvic girdle muscle weakness (mean age 34.4, 20-55), accompanied by asymmetrical atrophy of the quadriceps femoris and biceps brachii. 21 Though calf hypertrophy can be observed at presentation, they may develop later in the course asymmetrical mild calf atrophy usually not associated with weakness. No distal weakness in the upper limbs was observed. None of the LGMD2L patients lost walking, though the proximal weakness led to difficulties climbing stairs. The intrafamilial variability is striking with two patients reporting no symptoms at ages 68 (IX-II-3) and 61 (XXXI-II-3), though mild iliopsoas weakness was documented on examination and the creatine kinases (CK) levels were known to be elevated in the past years for both cases ( Table 1 ). The phenotype is quite different for MMD3 patients. The Dutch patients (family IV) showed early calf weakness, along with difficulties of walking on tiptoes, without atrophy. 23, 24 In the Finnish patients (family H), calf hypertrophy was seen in both cases during the early stages of their disease, but case H-II-6 later developed asymmetric calf atrophy. Despite the hypertrophy, calf weakness has always been an initial manifestation of all MMD3 cases. Asymmetric involvement of the proximal muscles of the lower and upper limb-girdles is a later manifestation with quadriceps atrophy being observed with time in two out of five MMD3 patients (Table 1 and Table  S1 ). The FC case XXIX-II-1, which shares the exon 5 c.191 dupA mutation with the MMD3 Dutch Family IV, had a somewhat overlapping LGMD2L and MMD3 phenotype. At age 63, she had concomitant late-onset asymmetrical proximal upper limb (deltoid, biceps, triceps) and ilopsoas weakness and distal upper limb (wrist and finger extensors) and tibialis anterior weakness, while having asymmetrical normal strength gastrocnemius hypertrophy. CK were elevated in all patients (1032-15860IU, mean 5514IU).
No cardiac abnormalities were detected on electrocardiomyogram (ECG), Holter ECG, and echocardiography for the FC and the Dutch patients. Electron microscopy performed on muscle from the LGMD2L patient IX-II-9 21 and MMD3 patient H-II-6 ( Figure 2C ) both showed multifocal disruption of the sarcolemmal membrane but no subsarcolemmal vesicle accumulation, as has been reported in dysferlinopathies. 30, 31 Furthermore, in the MMD3 Family H, membrane repair capability was found to be defective in patient fibroblasts by testing membrane resealing ability via either multiphoton laser irradiation or glass-beadmediated wounding in the presence of fluorescent dyes, Patients IX-II-9 and XXXI-II-11 are homozygous for c.1295C>G, causing an aberrant splicing in exon 13, a frameshift, and a premature termination codon. Patient XXIX-II-1 is heterozygote for c.191 dupA, causing a frameshift and a premature stop codon, and for c.692G>T, predicted to result in a missense. (B) The differential expression represents the ANO5 expression ratio of cycloheximide-treated versus untreated cells. Cases homozygous for c.1295C>G (n ¼ 2) showed an 8-fold increase, which was significantly greater than the 2-fold differential increase observed in controls (n ¼ 3, p < 0.001, Student's t test). Data represent the mean differential expression 5 standard error of, respectively, three control samples and two case samples. 21, 23, 24 ). b Patients homozygous for the mutation.
whereas lysosomal and enlargeosomal exocytosis was shown to occur normally, indicating that the conventional membrane repair pathways were not disrupted. 24 Until recently the function of the Anoctamins was unknown. The ten human ANO proteins share an eight transmembrane domain structure, which led to their earlier classification as the TransMEMbrane Protein 16 (TMEM16) family, and a DUF590 domain of unknown function. 13, 32 Three recent reports have demonstrated that ANO1 corresponds to the elusive calcium-activated chloride channel (CaCC). [15] [16] [17] In one of these studies, Schroeder et al. demonstrated that Ano1 coded for the CaCC responsible for polyspermia blockade in Xenopus oocytes. 16 Since then several other independent studies confirmed that ANO1 and ANO2 function as CaCC in mouse and in human. [18] [19] [20] 33, 34 ANO6, ANO8, and ANO9
were also confirmed to be chloride channels implicated in the control of cellular volume. 20 Because of the significant structural similarity between members of the Anoctamin family, it is predicted that all these proteins, including ANO5, are likely to function as CaCC. The physiological roles attributed to CaCC, ranging from epithelial transport of electrolytes, cell volume control, olfactory and photoreceptor transduction, and cardiac membrane excitability to smooth muscle contraction, still remain unclear in many tissues. 35 Until now no CaCC conductance has been reported in the plasma membrane of skeletal muscles, but the high sarcolemmal chloride conductance owing to the voltage-dependant chloride channel (CLCN1 [MIM 118425]) may have precluded the electrophysiological observation of such activity. 36 Calcium-activated chloride channels have also been reported in sarcoplasmic reticulum vesicles from rabbit skeletal muscles 37 but appeared to respond to much higher calcium concentrations than the one observed for ANO1. 17 A chloride current has been observed after membrane wounding of sea urchin embryos, 38 which raises the possibility that ANO5 may be responsible for a chloride current needed during membrane repair in human muscle. Several additional lines of evidence suggest that ANO5 may be important in the development and maintenance of skeletal muscle: ANO5 during embryogenesis is first expressed in the somites, particularly in the myotomal cells, and then in the muscle progenitor cells; 29 it is mostly expressed in skeletal muscle tissue in adult mice 25 and in skeletal muscle and cardiac tissues in human; 28 its expression is increased in dystrophin-deficient mdx mice muscle; 29 and lastly ANO5 is upregulated during myogenic differentiation of cultured cells (C2C12, Sol8, L6). 29 The identification of recessive ANO5 mutations in patients with muscular dystrophies associated with sarcolemmal membrane lesions on electron microscopy and defective membrane repair documented on one MMD3 family raise the possibility that ANO5 may play an important role in the dysferlin-dependent muscle membrane repair pathway. By biochemical fractionation ANO5 has been shown to be present at the membrane and in vesicles in L6 myotubes and mouse skeletal muscle. 29 Dysferlin shows a similar distribution in C2C12 myotubes and muscle tissue. 39, 40 Dysferlin was identified as the first protein component of the sarcolemmal repair machinery and is predicted to function as a fusogen in the formation of the patch membrane required for membrane resealing. 8 Other proteins mediating with dysferlin in muscle membrane repair have been identified and include Tripartite motif-containing 72 (TRIM72), 41 Annexins (MIM 151690, 151740), 42, 43 AHNAK (MIM 103390), 44 and Caveolin-3. 6, 45 It could be hypothesized that ANO5 present in vesicular membranes may respond to the intracellular calcium influx known to occur with membrane damage 46 by leading to a chloride influx in the vesicle that modifies its conformation so that it is recruited to the damage site. 8 The observation that ANO5 mutations, as in dysferlinopathy, can lead to both a proximal and a distal muscular dystrophy further suggests that anoctaminopathies may also cause skeletal muscle demise through defective membrane repair.
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